Business Context and Reporting Period
Company: BioCardia, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: March 17, 2026
Reporting Period: Single event date (March 17, 2026)
BioCardia, Inc., a Delaware corporation, filed this report to disclose a significant regulatory milestone regarding its Helix Transendocardial Delivery Catheter ("Helix"). The company is listed on The Nasdaq Capital Market under the symbol BCDA.
Key Financial Metrics
This Form 8-K is an event-driven filing and does not contain financial statements, revenue figures, profit data, cash flow information, margins, debt levels, or liquidity metrics. The filing text does not provide a clear value for any financial performance indicators.
Material Changes
The material change reported is a regulatory development rather than a financial one:
- Regulatory Acceptance: On March 17, 2026, the U.S. Food and Drug Administration (FDA) accepted BioCardia's pre-submission package for the Helix device.
- Device Purpose: The Helix catheter is intended for intramyocardial therapeutic and diagnostic agent delivery.
Guidance, Outlook, and Risks
Management Commentary: The filing references a press release (Exhibit 99.1) announcing the FDA acceptance but does not include specific forward-looking guidance, financial outlook, or detailed management commentary within the text of the 8-K itself.
Risks and Contingencies: The filing notes that the information provided in Item 8.01 and the attached press release is "furnished" and not "filed" for purposes of Section 18 of the Exchange Act. Consequently, this information is not subject to the liabilities of that section nor incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Verify the full text of the press release attached as Exhibit 99.1 for specific details on the FDA pre-submission process and next steps.
- Confirm the current status of the Helix Transendocardial Delivery Catheter clinical trials or regulatory timeline in subsequent filings.
- Review the company's most recent 10-K or 10-Q for financial health, cash runway, and debt obligations, as this 8-K contains no financial data.
- Monitor for any future 8-K filings regarding the FDA's formal response to the pre-submission package.